Display options
Cite
Lança T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology. 2012;1(5):717-725doi: 10.4161/onci.20068.
Lança, T., & Silva-Santos, B. (2012). The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology, 1(5), 717-725. https://doi.org/10.4161/onci.20068
Lança, Telma, and Silva-Santos, Bruno. "The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy." Oncoimmunology vol. 1,5 (2012): 717-725. doi: https://doi.org/10.4161/onci.20068
Lança T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology. 2012 Aug 01;1(5):717-725. doi: 10.4161/onci.20068. PMID: 22934263; PMCID: PMC3429575.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2012 Aug 01;1(5):717-725. doi: 10.4161/onci.20068.

The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy.

Oncoimmunology

Telma Lança, Bruno Silva-Santos

Affiliations

  1. Instituto de Medicina Molecular; Faculdade de Medicina; Universidade de Lisboa; Lisbon, Portugal.

PMID: 22934263 PMCID: PMC3429575 DOI: 10.4161/onci.20068

Abstract

An important development in tumor immunology was the identification of highly diverse tumor-infiltrating leukocyte subsets that can play strikingly antagonistic functions. Namely, "anti-tumor" vs. "pro-tumor" roles have been suggested for Th1 and Th17 subsets of CD4(+) T cells, Type I or Type II NKT cells, M1 and M2 macrophages, or N1 and N2 neutrophils, respectively. While these findings are being validated in cancer patients, it is also clear that the balance between infiltrating CD8(+) cytotoxic and Foxp3(+) regulatory T cells has prognostic value. Here we review the pre-clinical and clinical data that have shaped our current understanding of tumor-infiltrating leukocytes.

References

  1. Cancer Res. 2010 Apr 1;70(7):2665-74 - PubMed
  2. Cancer Res. 2011 Aug 15;71(16):5412-22 - PubMed
  3. Ann Oncol. 2009 Oct;20(10):1688-96 - PubMed
  4. Med Oncol. 2012 Sep;29(3):1817-26 - PubMed
  5. Eur J Immunol. 2010 Jul;40(7):1873-6 - PubMed
  6. J Immunol. 2009 Apr 15;182(8):4499-506 - PubMed
  7. Cancer Immunol Immunother. 2010 Jun;59(6):851-62 - PubMed
  8. J Immunother. 2010 May;33(4):435-41 - PubMed
  9. N Engl J Med. 2011 Aug 25;365(8):725-33 - PubMed
  10. Nat Rev Immunol. 2010 Aug;10(8):554-67 - PubMed
  11. Eur J Immunol. 2010 Jul;40(7):1927-37 - PubMed
  12. Blood. 2011 Jul 28;118(4):992-1001 - PubMed
  13. J Exp Med. 2009 Jul 6;206(7):1457-64 - PubMed
  14. Science. 2011 Jan 7;331(6013):44-9 - PubMed
  15. Immunity. 2008 Apr;28(4):571-80 - PubMed
  16. J Exp Med. 2005 Dec 19;202(12):1627-33 - PubMed
  17. J Clin Oncol. 2006 Dec 1;24(34):5373-80 - PubMed
  18. J Exp Med. 2011 Mar 14;208(3):491-503 - PubMed
  19. Crit Rev Oncol Hematol. 2012 Jun;82(3):296-309 - PubMed
  20. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5540-4 - PubMed
  21. Cancer Immunol Immunother. 2011 Oct;60(10):1419-30 - PubMed
  22. Cell. 2010 Apr 2;141(1):52-67 - PubMed
  23. J Exp Med. 2003 Aug 4;198(3):433-42 - PubMed
  24. J Exp Med. 2005 Nov 7;202(9):1279-88 - PubMed
  25. Lancet Oncol. 2012 Jan;13(1):e32-42 - PubMed
  26. Blood. 2009 Jul 9;114(2):357-9 - PubMed
  27. Clin Cancer Res. 2008 Jun 1;14(11):3254-61 - PubMed
  28. J Exp Med. 2008 Jun 9;205(6):1381-93 - PubMed
  29. Nature. 2011 Feb 24;470(7335):548-53 - PubMed
  30. Immunol Rev. 2011 May;241(1):104-18 - PubMed
  31. Gut. 2012 Mar;61(3):427-38 - PubMed
  32. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80 - PubMed
  33. J Hepatol. 2009 May;50(5):980-9 - PubMed
  34. Haematologica. 2008 Feb;93(2):193-200 - PubMed
  35. J Clin Invest. 2006 Aug;116(8):2132-2141 - PubMed
  36. Ann Oncol. 2005 Apr;16(4):590-6 - PubMed
  37. Nat Med. 2010 Feb;16(2):219-23 - PubMed
  38. Immunity. 2011 Dec 23;35(6):972-85 - PubMed
  39. J Exp Med. 2011 Sep 26;208(10):1949-62 - PubMed
  40. J Clin Oncol. 2007 Jun 20;25(18):2586-93 - PubMed
  41. Nat Rev Immunol. 2010 Jul;10(7):490-500 - PubMed
  42. Cancer Immunol Immunother. 2005 Aug;54(8):721-8 - PubMed
  43. J Clin Pathol. 2012 Feb;65(2):159-63 - PubMed
  44. Immunol Rev. 2011 Jan;239(1):27-44 - PubMed
  45. Clin Cancer Res. 2006 Jan 15;12(2):465-72 - PubMed
  46. Cancer Res. 2001 May 15;61(10):3932-6 - PubMed
  47. Cancer Res. 2010 Dec 15;70(24):10112-20 - PubMed
  48. Nature. 2011 Jul 13;475(7355):226-30 - PubMed
  49. Blood. 2009 Aug 6;114(6):1141-9 - PubMed
  50. Eur J Immunol. 2011 Sep;41(9):2522-5 - PubMed
  51. Curr Opin Immunol. 2011 Apr;23(2):272-8 - PubMed
  52. Genes Dev. 2010 Feb 1;24(3):241-55 - PubMed
  53. Nat Med. 2004 Sep;10(9):942-9 - PubMed
  54. PLoS One. 2011 Mar 31;6(3):e18219 - PubMed
  55. Br J Cancer. 2011 Jul 26;105(3):366-71 - PubMed
  56. J Clin Oncol. 2011 Feb 20;29(6):610-8 - PubMed
  57. PLoS Biol. 2011 Sep;9(9):e1001162 - PubMed
  58. Nat Rev Immunol. 2007 May;7(5):329-39 - PubMed
  59. EMBO Rep. 2007 Nov;8(11):1024-30 - PubMed
  60. Cancer Res. 2010 Apr 1;70(7):2697-706 - PubMed
  61. J Clin Oncol. 2009 Oct 1;27(28):4709-17 - PubMed
  62. Cancer Res. 2010 Apr 15;70(8):3052-61 - PubMed
  63. Blood. 2008 Jul 15;112(2):362-73 - PubMed
  64. Curr Opin Immunol. 2010 Apr;22(2):199-205 - PubMed
  65. Blood. 2012 Mar 22;119(12):2709-20 - PubMed
  66. Cancer Res. 2011 Feb 15;71(4):1263-71 - PubMed
  67. Cell Cycle. 2010 May;9(9):1732-7 - PubMed
  68. Clin Immunol. 2011 Aug;140(2):117-8 - PubMed
  69. Cancer Cell. 2009 Sep 8;16(3):183-94 - PubMed
  70. Science. 2001 Oct 19;294(5542):605-9 - PubMed
  71. J Clin Invest. 2010 Apr;120(4):1151-64 - PubMed
  72. J Immunol. 2008 May 1;180(9):6044-53 - PubMed
  73. J Clin Oncol. 2009 Dec 10;27(35):5944-51 - PubMed
  74. Cancer Cell. 2011 Sep 13;20(3):300-14 - PubMed
  75. Immunity. 2009 Nov 20;31(5):787-98 - PubMed
  76. Oncoimmunology. 2012 Jan 1;1(1):38-47 - PubMed
  77. Cancer Immunol Immunother. 2010 May;59(5):653-61 - PubMed
  78. J Exp Med. 2008 Jul 7;205(7):1673-85 - PubMed
  79. J Exp Med. 2004 Mar 15;199(6):879-84 - PubMed
  80. J Exp Med. 2011 Mar 14;208(3):469-78 - PubMed
  81. Cancer Res. 2010 Dec 15;70(24):10024-7 - PubMed
  82. Cancer Res. 2011 Jul 15;71(14):4809-20 - PubMed
  83. Blood. 2010 Mar 25;115(12):2407-11 - PubMed
  84. Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74 - PubMed
  85. Nat Immunol. 2009 Apr;10(4):427-36 - PubMed
  86. J Exp Med. 2010 Aug 2;207(8):1791-804 - PubMed
  87. Nat Immunol. 2010 Oct;11(10):889-96 - PubMed
  88. Cancer Res. 2003 Apr 1;63(7):1555-9 - PubMed
  89. Nat Med. 2011 Jun;17(6):700-7 - PubMed
  90. Blood. 2009 Jun 18;113(25):6382-5 - PubMed
  91. J Exp Med. 2008 Jun 9;205(6):1261-8 - PubMed
  92. Nat Rev Clin Oncol. 2011 Aug 02;8(10):577-85 - PubMed
  93. Cancer Immunol Immunother. 2011 Jul;60(7):909-18 - PubMed
  94. Cancer Res. 2011 Sep 1;71(17):5678-87 - PubMed
  95. Trends Immunol. 2011 Jan;32(1):19-25 - PubMed

Publication Types